- Datum10.05.2024
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
Deciphera Pharmaceuticals Inc. Registered Shares DL -,01
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Deciphera Pharmaceuticals Inc. Registered Shares DL -,01 Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,04 %
Intraday
0,04 %
1 Woche
69,02 %
1 Monat
57,28 %
Seit Jahresbeginn
87,09 %
1 Jahr
-26,10 %
3 Jahre
5,49 %
5 Jahre
Wikifolio
Passender Service zu Deciphera Pharmaceuticals Inc. Registered Shares DL -,01
Webinar zu Deciphera Pharmaceuticals Inc. Registered Shares DL -,01
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)9,900-25,470
- Jahrestief / Hoch ($)13,250-25,470
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Deciphera Pharmaceuticals Inc. Registered Shares DL -,01
Keine Dividenden verfügbar
Termine von Deciphera Pharmaceuticals Inc. Registered Shares DL -,01
- Aug1Deciphera Pharmaceuticals Inc. Registered Shares DL -,01Q2 2024 Earnings Release
- Okt30Deciphera Pharmaceuticals Inc. Registered Shares DL -,01Q3 2024 Earnings Release
Beschreibung
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
